Clinical trials: Acute Infection Respiratory
COVID-19
Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine
This is a double blind, placebo controlled study in approximately 2,000 health care workers at risk for being exposed to COVID-19.
- Trial name
- HERO-HCQ (NCT04334148)
- Testing
- Hydroxychloroquine
- Where
- 34 sites in United States
- Volunteers
- 1,360 people, healthy volunteers welcome
- Sponsor
- Adrian Hernandez
Community-acquired Pneumonia, Acute Otitis Media
Using Electronically Derived Automated Reports of Appropriate Antibiotic Use to Inform Stewardship Interventions
The main goal of this study is to use automated electronic reports to assess and improve guideline-concordant antibiotic use for: 1) adult inpatients with community-acquired pneumonia; 2) pediatric inpatients with…
- Conditions
- Community-acquired Pneumonia, Acute Otitis Media, Pharyngitis
- Trial name
- EMPOWER (NCT06027593)
- Testing
- Quasi experimental intervention
- Where
- 2 sites in United States
- Volunteers
- 26,139 people
- Sponsor
- Children's Hospital of Philadelphia
Healthy
A Pilot Study of the Safety, Tolerability, and Effectiveness of Halo
This is a pilot study of the safety, tolerability, and effectiveness of Halo to prevent acute upper respiratory illness and respiratory virus infections.
- Trial name
- NCT02644135
- Testing
- Halo Oral Spray
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospitals Cleveland Medical Center
Respiratory Distress Syndrome, Adult, Sepsis
Early Insulin and Development of ARDS
Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS) is a severe lung condition that causes respiratory failure. Symptoms usually develop within 24 to 48 hours of an original injury or illness, and people with…
- Conditions
- Respiratory Distress Syndrome, Adult, Sepsis, Hyperglycemia
- Trial name
- NCT00605696
- Testing
- Insulin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Albert Einstein College of Medicine
COVID-19
Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease
This study evaluates the efficacy and safety of intravenous (IV) infusions of pamrevlumab when compared with placebo in participants who are hospitalized with acute COVID-19 disease.
- Trial name
- NCT04432298
- Testing
- Pamrevlumab
- Where
- 4 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Kyntra Bio
Community Acquired Pneumonia
Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
The aim of this study is to test if BPS (Bacterial Pneumonia Score) guided antibiotic use in children with non severe community acquired pneumonia (CAP) and pneumoccocal vaccine will reduce antibiotic use as compared to standard…
- Trial name
- NCT01875731
- Testing
- BPS, Guideline
- Where
- Argentina
- Volunteers
- 66 people
- Sponsor
- Hospital General de Niños Pedro de Elizalde
Sinusitis
BAY12-8039: 5 Days for Sinusitis vs Placebo
The purpose of the study is to evaluate the effectiveness and safety of Avelox in a 5 day treatment of adult patients with acute bacterial sinusitis and to measure the amount of time it takes for symptom relief.
- Trial name
- NCT00492024
- Testing
- Moxifloxacin (Avelox, BAY12-8039)
- Where
- 51 sites in United States
- Volunteers
- 374 people
- Sponsor
- Bayer
Solid Tumors and Hematologic Malignancy
An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
This was a study of INCB054329 given to patients with advanced malignancies that were conducted in three treatment groups. Each treatment group had a dose escalation (Part 1) and a dose expansion (Part 3), two of the treatment…
- Trial name
- NCT02431260
- Testing
- INCB054329 Monotherapy
- Where
- 12 sites in United States
- Volunteers
- 69 people
- Sponsor
- Incyte Corporation
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Acute Respiratory Distress Syndrome, Influenza
STIP: Statin Trial for Influenza Patients
To assess the efficacy and safety of oral rosuvastatin in patients with suspected or confirmed influenza who require intensive care unit (ICU) admission due to respiratory distress.
- Conditions
- Acute Respiratory Distress Syndrome, Influenza, H1N1 Influenza
- Trial name
- STIP (NCT00970606)
- Testing
- Rosuvastatin (crestor)
- Where
- 21 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gordon Bernard
Influenza
Mechanisms of Severe Acute Influenza Consortium (MOSAIC)
The ultimate goal of this collaborative, intensive study is to discover new and effective treatments and to develop better vaccines that can be used in future outbreaks of Influenza A.
- Trial name
- MOSAIC (NCT00965354)
- Where
- 8 sites in United Kingdom
- Volunteers
- 131 people
- Sponsor
- Imperial College London
Acute Otitis Media, Acute Sinusitis
Comparative Effectiveness of Antibiotics for Respiratory Infections
The purpose of this study is to identify and use patient centered outcomes to compare narrow-spectrum and broad-spectrum antibiotics for the treatment of common acute respiratory tract infections (ARTIs) in children.
- Conditions
- Acute Otitis Media, Acute Sinusitis, Group A Streptococcal Pharyngitis
- Trial name
- CEARI (NCT02297815)
- Testing
- Broad-spectrum antibiotics, Narrow-spectrum antibiotics
- Where
- United States
- Volunteers
- 2,472 people
- Sponsor
- Children's Hospital of Philadelphia
Severe Acute Respiratory Syndrome
Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
To determine if the reduction in TMPRSS2 activity via direct inhibition with Camostat mesilate combined with standard of care (SOC) treatment will increase the proportion of patients alive and free from respiratory failure at Day…
- Trial name
- RECOVER (NCT04470544)
- Testing
- Camostat Mesilate, Standard of Care
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Alan Bryce
Postural Orthostatic Tachycardia Syndrome
Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS
The study aims to investigate the safety, tolerability, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity of efgartigimod compared to placebo in participants with post-COVID-19 postural orthostatic…
- Trial name
- POTS (NCT05633407)
- Testing
- Efgartigimod
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- argenx
Heart Failure, Respiratory Insufficiency
A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) events and VTE-related death post-hospital discharge in…
- Conditions
- Heart Failure, Respiratory Insufficiency, Stroke Acute, Infectious Diseases
- Trial name
- MARINER (NCT02111564)
- Testing
- Rivaroxaban, 10 mg, Rivaroxaban, 7.5 mg
- Where
- 593 sites in United States, Argentina and 35 more
- Volunteers
- 12,024 people
- Sponsor
- Janssen Research & Development, LLC
Severe Acute Respiratory Syndrome, Respiratory Failure
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
The global pandemic COVID-19 has overwhelmed the medical capacity to accommodate a large surge of patients with acute respiratory distress syndrome (ARDS).
- Conditions
- Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04357730
- Testing
- Alteplase 50 MG [Activase]
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Denver Health and Hospital Authority
Coronavirus, Coronavirus Infection
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate…
- Conditions
- Coronavirus, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2, Pneumonia
- Trial name
- CYNKCOVID (NCT04365101)
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- Celularity Incorporated
Chronic Bronchitis
A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB)
This trial is a research drug study to compare the effects of two antibiotics for the treatment of acute exacerbation of chronic bronchitis
- Trial name
- NCT00254566
- Testing
- Moxifloxacin, Azithromycin SR
- Where
- 34 sites in China, Malaysia and 4 more
- Volunteers
- 398 people
- Sponsor
- Pfizer
Traumatic Brain Injury, Fatigue
Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy
Patients with a history of mild traumatic brain injury (mTBI) or post acute sequelae of SARS-CoV-2 (PASC) and abnormal growth hormone secretion, as measured by glucagon stimulation test, will be treated with replacement growth…
- Conditions
- Traumatic Brain Injury, Fatigue, Cognitive Impairment, COVID-19
- Trial name
- NCT03554265
- Testing
- Somatropin
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Post-COVID-19 Syndrome
Cognitive Rehabilitation in Post-COVID-19 Syndrome
The first aim of this study is to determine the feasibility of delivering CO-OP remotely to individuals experiencing cognitive impairments that limit everyday activities in post-COVID-19 syndrome (PCS).
- Trial name
- NCT06136871
- Testing
- CO-OP Procedures, Inactive Control Group
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- University of Missouri-Columbia